Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Carcinoma, Non-Small-Cell Lung 10Neurofibromatosis 1 9Breast Neoplasms 5Neurofibroma, Plexiform 4Lung Neoplasms 4Triple Negative Breast Neoplasms 3Neurofibrosarcoma 3Thyroid Neoplasms 2Neoplasms 2Melanoma 2Gallbladder Neoplasms 2Uveal Melanoma 1Thyroid Diseases 1Thyroid Cancer, Papillary 1Sarcoma, Kaposi 1Sarcoma 1Recurrence 1Rectal Neoplasms 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Optic Nerve Glioma 1Non-small Cell Lung Cancer Metastatic 1Neuroma, Acoustic 1Neurofibromatosis 2 1Neoplasm Metastasis 1Meningioma 1Liver Neoplasms 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Glioma 1

Interventions

Cyclophosphamide 57fludarabine phosphate 48Tacrolimus 39Peripheral Blood Stem Cell Transplantation 37Busulfan 36Mycophenolic Acid 34Whole-Body Irradiation 31Antilymphocyte Serum 28Methotrexate 26Cyclosporine 25fludarabine 23Melphalan 18Filgrastim 15Radiotherapy 14thymoglobulin 12ruxolitinib 12Methylprednisolone 12Cord Blood Stem Cell Transplantation 12Stem Cell Transplantation 11Sirolimus 11Psychiatric Rehabilitation 9Flow Cytometry 9Etoposide 9Specimen Handling 7Granulocyte Colony-Stimulating Factor 7merphos 6Therapeutics 6Decitabine 6Cyclosporins 6Azacitidine 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Primary Myelofibrosis × AZD 6244 × Clear all
NCT03326310 2025-12-29

Selumetinib and Azacitidine in High Risk Chronic Blood Cancers

University of Chicago

Phase 1 Recruiting
18 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡